Next Phase Newsletter

A firm based in the Eastern US that has managed two venture capital funds in the past, is currently making angel investments from the founders private funds. These investments are typically $1-3m, but are highly varied and may be higher. The firm is focused on investing in US-based companies.

The firm invests in a range of industries, and within the life science sector the firm is focused on investing in medical devices. The firm will consider opportunities in any areas of medical technology and in any indication area, but is particularly interested in products that present an easier regulatory route and a quicker time to market. The firm prefers to invest in products that have already entered clinical trials. The firm does not invest in instrumentation/lab equipment.

The firm does not have any specific requirements for companies and management teams, but generally only invests in pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

​A venture capital company with office on the east and west coasts of the United States is currently making investments out of its 1st $180 million fund and is capable of making investments ranging from $5-$20 million into selected companies. The firm has made both equity and convertible note investments and is looking to make 3-6 investments over the next 6-9 months. The firm is looking for companies located globally.

The firm is looking to invest in the Therapeutics space and is open to considering both small molecules and biologics. The firm is looking for companies in the clinical stage that are at least post proof of concept. The firm is generally open to all subsectors and indications including orphan diseases.

​The firm is looking for management teams with experience that are backed d by strong science and a solid strategy. The firm looks to act as a hands on investor generally taking a board seat following investment. The firm is open to investing in both private and publically held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The Corporate Venture Capital Arm of large pharma company is currently investing from its second fund of $100M. The firm invests in early-stage biotechnology companies focusing on discovering and developing human therapeutics primarily in the areas of the current therapeutic interest to the firm’s parent company. The firm typically invests (equity) $3-$4M per round with $10M reserved for follow-on investments. The firm seeks companies that are based in the US and Europe. The firm seeks to make about 2-3 allocations in the next 6-9 months.

The firm seeks early-stage companies developing human therapeutics. The firm is seeking companies with products in pre-clinical to phase IIa. The firm’s therapeutic areas of focus are: Cardiovascular (Acute Coronary Syndromes, Dyslipidemia, Heart Failure); Hematology (Anemia, Neutropenia, Stem Cell Mobilization); Inflammation (Asthma, Bowel Disease, Multiple Sclerosis, Osteoarthritis, Psoriasis, Rheumatoid arthritis, Systemic Lupus Erythematosus); Metabolic Disorders (Diabetes, Osteoporosis); Nephrology (Hyperparathyroidism, Renal Failure); Neuroscience (Alzheimer’s Disease, Cognition, Pain-Neuropathic & Inflammatory, Parkinson’s Disease, Schizophrenia); and Oncology. The firm is also interested in drug delivery therapeutics and Healthcare IT

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An innovative global private equity firm utilizing a virtual pharma (asset centric) model is looking to invest in early stage pharmaceutical assets, and is capable of providing $15-$20 million or more to get a project through proof of concept. The firm prefers to acquire or in-license individual pharmaceutical assets and is much less likely to make traditional equity investments into companies. Ideal candidates have yet to receive significant VC funding and the firm prefers to invest without syndicates. The firm in interested in investing in projects around the globe and is capable of making 15+ investments over the course of the next year if enough high quality investments present themselves.

The firm is looking primarily for pharmaceutical assets and to a much lesser extent diagnostics and medical devices. The firm is willing to invest in assets that are as far as 12-18 months pre-IND to those that are early in phase I of clinical trials and ideal candidates are IND ready and preparing to enter phase I. The firm is open to all indications where proof of concept can be shown in early clinical trials which generally excludes assets targeting a number of CNS disorders. For medical device and diagnostic opportunities only very select programs of extreme appeal will be considered.

The firm is looking to partner with management teams that have an extreme understanding of the science behind their product and that are willing to operate in a virtual environment. The firm acts as an extremely hands on investor often integrating investments into the parent company and ensuring that all assets are developed in the most effective and risk-diversified manner.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Private Equity group based in the Eastern United States is looking for new firms for potential investments for the firm’s third fund and could make as many as 10 investment over the next year. The firm looks to make equity investments into companies looking to raise a total round of $20-$50 million generally set up in tranches. The firm looks to invest in companies across the United States and Europe with a focus on companies located in the United States.

The firm is interested in Therapeutics, Medical Devices and Diagnostics, though the majority of the firm’s investments have been into the therapeutics space. The firm is primarily interested in later stage opportunities, with a focus on therapeutics that are in Phase II or later and devices and diagnostics that are well into their clinical trial or are already on the market. The firm is opportunistic across technologies types and indications although historically they have worked with a number of companies in the oncology and infectious disease spaces.

The firm is looking for companies with significant competitive advantage and strong, experienced management teams. The firm is willing to invest in both public and privately held companies with a preference for those that are private. The firm is open to both lead and co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm that is based in the Eastern United States is looking to make equity investments into early stage companies of under $1 million generally in the Seed or Series A Round. The firm is also very open to syndication with other investors for larger rounds. The firm is looking for companies throughout the United States and is actively seeking new investment opportunities.                  

Within the life science space the firm is interested in companies that are leveraging advanced materials science in sub sectors of bio materials, diagnostics, analytics, and life science tools/services. Current portfolio companies in the space include companies developing improved therapeutics via biophysical and surface engineering, instruments and consumables for genetic analysis, DNA directed synthesis applied to human therapeutics and clinical diagnostics, and specialty enzymes for medical, biofuel, and industrial applications.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role in its portfolio companies and generally looks to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of an international healthcare company is currently making equity investments out of a $200 million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

The firm is primarily interested in companies that are of strategic interest to its parent company. These include innovative companies developing Therapeutics, Diagnostics, Medical Technology and Healthcare IT. In the therapeutics space the firm is highly interest in Gene therapy and is also open to companies working with small molecules and biologics. In the Medical Device Space the firm is generally open to all technology types including, Fluid Management Systems, Infusion Systems/IV Tubing, Software enabled devices, Home Care, Hospital Hardware and Drug Delivery Devices. For indications the firm is interested in areas of Oncology, Hematology, Immunology, Inflammation, and Pulmonology, Renal, Regenerative Medicine and Orphan Diseases. The firm is stage agnostic and will consider companies from the pre-clinical phase to those that already have products on the market. The firm is not interested in companies working with laboratory tools or technology that aids in the research/discovery process in the life science space.

The firm is looking for privately held companies and while they prefer companies to have a complete management team in place they are also open to working with companies to fill in gaps in management. The firm will lead investments although they generally prefer to co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com